Lloyd-Thomas A R, Wright I, Lister T A, Hinds C J
St Bartholomew's Hospital, London.
Br Med J (Clin Res Ed). 1988 Apr 9;296(6628):1025-9. doi: 10.1136/bmj.296.6628.1025.
The mortality of patients admitted to intensive care units with haematological malignancy is high. A humane approach to the management of the critically ill as well as efficient use of limited resources requires careful selection of those patients who are most likely to benefit from intensive care. To delineate more accurately the factors influencing outcome in these patients the records of 60 consecutive admissions to the intensive care unit (37 male, 23 female) with haematological malignancy were reviewed retrospectively. Fifty patients were in acute respiratory failure, most commonly (34 patients) with a combination of pneumonia and septicaemic shock. The severity of the acute illness was assessed by the APACHE II (acute physiology and chronic health evaluation II) score and number of organ systems affected. Thirteen patients survived to leave hospital. The mortality of patients with haematological malignancy was consistently higher than predicted from a large validation study of APACHE II in a mixed population of critically ill patients. Moreover, no patient with an APACHE II score of greater than 26 survived. Mortality among the 22 patients with relapsed malignancy (21 deaths), was significantly higher than among the 35 patients at first presentation (26 deaths). On discharge from the intensive care unit all survivors had responded well to chemotherapy and had normal or raised peripheral white cell counts. They included seven patients who had recovered from leucopenia (white cell count less than 0.5 X 10(9)/l). In contrast, 36 of the 47 patients who died were leucopenic at the time of death. The overall mortality of critically ill patients with haematological malignancy is higher than equivalently ill patients without cancer. The dysfunction of an increasing number of organ systems, an APACHE II score of greater than 30, failure of the malignancy to respond to chemotherapy, and persistent leucopenia all point to a poor outcome.
入住重症监护病房的血液系统恶性肿瘤患者死亡率很高。要以人道方式管理重症患者并有效利用有限资源,就需要仔细挑选那些最有可能从重症监护中获益的患者。为了更准确地描述影响这些患者预后的因素,我们对60例连续入住重症监护病房的血液系统恶性肿瘤患者(37例男性,23例女性)的记录进行了回顾性分析。50例患者出现急性呼吸衰竭,最常见的情况(34例患者)是肺炎合并败血症性休克。通过急性生理与慢性健康状况评估II(APACHE II)评分以及受影响的器官系统数量来评估急性疾病的严重程度。13例患者存活出院。血液系统恶性肿瘤患者的死亡率始终高于对重症患者混合群体进行的APACHE II大型验证研究预测的死亡率。此外,APACHE II评分大于26的患者无一存活。22例复发恶性肿瘤患者中的死亡率(21例死亡)明显高于35例初诊患者中的死亡率(26例死亡)。从重症监护病房出院时,所有幸存者对化疗反应良好,外周血白细胞计数正常或升高。其中包括7例从白细胞减少症(白细胞计数低于0.5×10⁹/L)中康复的患者。相比之下,47例死亡患者中有36例在死亡时白细胞减少。重症血液系统恶性肿瘤患者的总体死亡率高于无癌症的同等病情患者。越来越多器官系统功能障碍、APACHE II评分大于30、恶性肿瘤对化疗无反应以及持续白细胞减少均表明预后不良。